

Jean-Philippe Merlio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2540543/publications.pdf>

Version: 2024-02-01

61
papers

2,689
citations

257429

24
h-index

182417

51
g-index

62
all docs

62
docs citations

62
times ranked

3641
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring <i>hTERT</i> promoter methylation in cutaneous T-cell lymphomas. <i>Molecular Oncology</i> , 2022, 16, 1931-1946.	4.6	12
2	Telomeric Repeat-Containing RNA (TERRA): A Review of the Literature and First Assessment in Cutaneous T-Cell Lymphomas. <i>Genes</i> , 2022, 13, 539.	2.4	6
3	Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. <i>Oncogene</i> , 2022, 41, 2571-2586.	5.9	6
4	Integrative diagnosis of primary cutaneous large B-cell lymphomas supports the relevance of cell of origin profiling. <i>PLoS ONE</i> , 2022, 17, e0266978.	2.5	4
5	Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 172, 85-95.	2.8	20
6	Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3243-3252.e10.	0.7	6
7	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021, 48, 100782.	5.7	7
8	Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity. <i>Leukemia</i> , 2021, 35, 1696-1709.	7.2	16
9	C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma. <i>Cancers</i> , 2021, 13, 270.	3.7	8
10	Lack of clinical relevance of blood clonality in primary cutaneous marginal zone B-cell lymphoma. <i>European Journal of Dermatology</i> , 2021, 31, 94-96.	0.6	3
11	Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1441-1451.	1.3	6
12	Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas. <i>Cancers</i> , 2021, 13, 4256.	3.7	1
13	CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells. <i>Nature Communications</i> , 2021, 12, 4922.	12.8	44
14	MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. <i>Human Pathology</i> , 2021, 114, 99-109.	2.0	16
15	A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival. <i>Blood Advances</i> , 2021, 5, 5372-5386.	5.2	18
16	Single-cell trajectories in Sézary syndrome. <i>Blood</i> , 2021, 138, 1384-1386.	1.4	1
17	Targeting Epigenetic Modifiers Can Reduce the Clonogenic Capacities of Sézary Cells. <i>Frontiers in Oncology</i> , 2021, 11, 775253.	2.8	3
18	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	3.0	17

#	ARTICLE	IF	CITATIONS
19	Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. <i>American Journal of Surgical Pathology</i> , 2020, 44, 424-427.	3.7	3
20	hMZf-2, the Elusive Transcription Factor. <i>Frontiers in Genetics</i> , 2020, 11, 581115.	2.3	1
21	Reliable blood cancer cells' telomere length evaluation by qPCR. <i>Cancer Medicine</i> , 2020, 9, 3153-3162.	2.8	13
22	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100052.	1.1	9
23	Circulating Tumor Cell Clusters: United We Stand Divided We Fall. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2653.	4.1	73
24	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2334-2342.e8.	0.7	28
25	Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. <i>Histopathology</i> , 2019, 74, 1067-1080.	2.9	28
26	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989.	0.7	27
27	Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. <i>Modern Pathology</i> , 2018, 31, 1332-1342.	5.5	31
28	Assessment of BRAFV600E mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 247-258.	2.8	10
29	Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination. <i>Cancers</i> , 2018, 10, 402.	3.7	7
30	SATB1 Is a Pivotal Epigenetic Biomarker in Cutaneous T-Cell Lymphomas. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1694-1696.	0.7	11
31	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1984-1994.	0.7	93
32	Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. <i>Annals of Oncology</i> , 2017, 28, 2715-2724.	1.2	72
33	TP53 alterations in primary and secondary Sezary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma. <i>PLoS ONE</i> , 2017, 12, e0173171.	2.5	13
34	Telomerase Activation in Hematological Malignancies. <i>Genes</i> , 2016, 7, 61.	2.4	25
35	Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene. <i>Genes</i> , 2016, 7, 133.	2.4	12
36	Intrahepatic Xenograft of Cutaneous T-Cell Lymphoma Cell Lines. <i>American Journal of Pathology</i> , 2016, 186, 1775-1785.	3.8	11

#	ARTICLE	IF	CITATIONS
37	MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1741-1744.	0.7	46
38	Proliferative Nodules vs Melanoma Arising in Giant Congenital Melanocytic Nevi During Childhood. <i>JAMA Dermatology</i> , 2016, 152, 1147.	4.1	21
39	SÃ©zary Syndrome: Translating Genetic Diversity into Personalized Medicine. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1319-1324.	0.7	16
40	Primary digestive melanoma in association with tubular adenoma: a case report illustrating the distinction from metastatic colonic melanoma. <i>Human Pathology</i> , 2016, 48, 167-171.	2.0	3
41	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet, The</i> , 2016, 387, 1415-1426.	13.7	790
42	Molecular alterations and tumor suppressive function of the <i>DUSP22</i> (Dual Specificity) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td	1.8	41
43	Diagnostic and Prognostic Value of <i>BCL2</i> Rearrangement in 53 Patients With Follicular Lymphoma Presenting as Primary Skin Lesions. <i>American Journal of Clinical Pathology</i> , 2015, 143, 362-373.	0.7	38
44	PLCG1 Gene Mutations Are Uncommon in Cutaneous T-Cell Lymphomas. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2334-2337.	0.7	16
45	Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. <i>PLoS ONE</i> , 2015, 10, e0120232.	2.5	24
46	Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2014, 27, 402-411.	5.5	78
47	BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. <i>Pathology</i> , 2014, 46, 311-315.	0.6	10
48	High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. <i>JAMA Dermatology</i> , 2014, 150, 1173.	4.1	110
49	Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma. <i>Blood</i> , 2014, 123, 1850-1859.	1.4	24
50	Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients. <i>Annals of Oncology</i> , 2013, 24, 742-748.	1.2	103
51	Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing. <i>PLoS ONE</i> , 2013, 8, e70826.	2.5	97
52	MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2118-2120.	0.7	85
53	IRF4 Gene Rearrangements Define a Subgroup of CD30-Positive Cutaneous T-Cell Lymphoma: A Study of 54 Cases. <i>Journal of Investigative Dermatology</i> , 2010, 130, 816-825.	0.7	114
54	Genome-Wide Analysis of Cutaneous T-Cell Lymphomas Identifies Three Clinically Relevant Classes. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1707-1718.	0.7	100

#	ARTICLE	IF	CITATIONS
55	CDKN2A—CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. <i>Modern Pathology</i> , 2010, 23, 547-558.	5.5	80
56	Primary Cutaneous T-Cell Lymphomas Do not Show Specific NAV3 Gene Deletion or Translocation. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2458-2466.	0.7	24
57	Common chromosomal abnormalities in mycosis fungoides transformation. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 828-838.	2.8	44
58	Large cell transformation of mycosis fungoides: tetraploidization within skin tumor large cells. <i>Cancer Genetics and Cytogenetics</i> , 2005, 163, 1-6.	1.0	21
59	Neoplastic Cells Do Not Carry bcl2-JH Rearrangements Detected in a Subset of Primary Cutaneous Follicle Center B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2004, 28, 748-755.	3.7	51
60	Evidence that an Identical T Cell Clone in Skin and Peripheral Blood Lymphocytes is an Independent Prognostic Factor in Primary Cutaneous T Cell Lymphomas. <i>Journal of Investigative Dermatology</i> , 2001, 117, 920-926.	0.7	74
61	Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations. <i>Blood</i> , 1998, 91, 4668-76.	1.4	18